ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Alternext US: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced today that it has initiated a Phase IIa clinical trial for SerdaxinTM, for the treatment of major depressive disorder (MDD). The Serdaxin Phase IIa study calls for the recruitment of up to 100 patients to evaluate its preliminary efficacy in treating MDD.
